RefCheck Maintenance Notice

On Monday, December 3, 2018, from 16:00-18:00 EST, RefCheck will be undergoing maintenance. RefCheck is the process where, during copyediting, all references are extracted from the manuscript file, parsed, matched against various databases (eg, PubMed and CrossRef), and automatically corrected. For more information on RefCheck, please visit our Knowledge Base.

Who will be affected?

Advertisement

Citing this Article

Right click to copy or hit: ctrl+c (cmd+c on mac)

Published on 20.09.17 in Vol 6, No 9 (2017): September

This paper is in the following e-collection/theme issue:

    Proposal

    Cancer Predisposition Cascade Screening for Hereditary Breast/Ovarian Cancer and Lynch Syndromes in Switzerland: Study Protocol

    1Nursing Science, Faculty of Medicine, University of Basel, Basel, Switzerland

    2University of Michigan School of Nursing, Ann Arbor, MI, United States

    3Unit of Oncogenetics and Cancer Prevention, Division of Oncology, Geneva University Hospitals, Geneva, Switzerland

    4University of Applied Sciences and Arts of Southern Switzerland, Manno, Switzerland

    5University Clinic for Medical Oncology, Inselspital Bern, Bern, Switzerland

    6Women’s Clinic and Gynecological Oncology, University Hospital Basel, University of Basel, Basel, Switzerland

    7Institute of Oncology (IOSI) and Breast Unit (CSSI) of Southern Switzerland, Bellinzona, Switzerland

    8University Clinic for Visceral Surgery and Medicine, Inselspital Bern, Bern, Switzerland

    9Clinical Trials Unit, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland

    10Swiss Tropical and Public Health Institute, University of Basel, Basel, Switzerland

    11Medical Genetics, University Hospital Basel, University of Basel, Basel, Switzerland

    12Division of Genetic Medicine, Geneva University Hospitals, University of Geneva, Geneva, Switzerland

    Swiss Cancer Predisposition Cascade Screening Consortium

    *these authors contributed equally

    Corresponding Author:

    Maria C Katapodi, Prof. Dr. PhD, RN, FAAN

    Nursing Science

    Faculty of Medicine

    University of Basel

    Bernoullistrasse 28

    Basel, 4056

    Switzerland

    Phone: 41 612070430

    Email:


    ABSTRACT

    Background: Breast, colorectal, ovarian, and endometrial cancers constitute approximately 30% of newly diagnosed cancer cases in Switzerland, affecting more than 12,000 individuals annually. Hundreds of these patients are likely to carry germline pathogenic variants associated with hereditary breast ovarian cancer (HBOC) or Lynch syndrome (LS). Genetic services (counseling and testing) for hereditary susceptibility to cancer can prevent many cancer diagnoses and deaths through early identification and risk management.

    Objective: Cascade screening is the systematic identification and testing of relatives of a known mutation carrier. It determines whether asymptomatic relatives also carry the known variant, needing management options to reduce future harmful outcomes. Specific aims of the CASCADE study are to (1) survey index cases with HBOC or LS from clinic-based genetic testing records and determine their current cancer status and surveillance practices, needs for coordination of medical care, psychosocial needs, patient-provider and patient-family communication, quality of life, and willingness to serve as advocates for cancer genetic services to blood relatives, (2) survey first- and second-degree relatives and first-cousins identified from pedigrees or family history records of HBOC and LS index cases and determine their current cancer and mutation status, cancer surveillance practices, needs for coordination of medical care, barriers and facilitators to using cancer genetic services, psychosocial needs, patient-provider and patient-family communication, quality of life, and willingness to participate in a study designed to increase use of cancer genetic services, and (3) explore the influence of patient-provider communication about genetic cancer risk on patient-family communication and the acceptability of a family-based communication, coping, and decision support intervention with focus group(s) of mutation carriers and relatives.

    Methods: CASCADE is a longitudinal study using surveys (online or paper/pencil) and focus groups, designed to elicit factors that enhance cascade genetic testing for HBOC and LS in Switzerland. Repeated observations are the optimal way for assessing these outcomes. Focus groups will examine barriers in patient-provider and patient-family communication, and the acceptability of a family-based communication, coping, and decision-support intervention. The survey will be developed in English, translated into three languages (German, French, and Italian), and back-translated into English, except for scales with validated versions in these languages.

    Results: Descriptive analyses will include calculating means, standard deviations, frequencies, and percentages of variables and participant descriptors. Bivariate analyses (Pearson correlations, chi-square test for differences in proportions, and t test for differences in means) will assess associations between demographics and clinical characteristics. Regression analyses will incorporate generalized estimating equations for pairing index cases with their relatives and explore whether predictors are in direct, mediating, or moderating relationship to an outcome. Focus group data will be transcribed verbatim and analyzed for common themes.

    Conclusions: Robust evidence from basic science and descriptive population-based studies in Switzerland support the necessity of cascade screening for genetic predisposition to HBOC and LS. CASCADE is designed to address translation of this knowledge into public health interventions.

    Trial Registration: ClinicalTrials.gov NCT03124212; https://clinicaltrials.gov/ct2/show/NCT03124212 (Archived by WebCite at http://www.webcitation.org/6tKZnNDBt)

    JMIR Res Protoc 2017;6(9):e184

    doi:10.2196/resprot.8138

    KEYWORDS

    Crowdfunding campaign to support this specific research

    We help JMIR researchers to raise funds to pursue their research and development aimed at tackling important health and technology challenges. If you would like to show your support for this author, please donate using the button below. The funds raised will directly benefit the corresponding author of this article (minus 8% admin fees). Your donations will help this author to continue publishing open access papers in JMIR journals. Donations of over $100 may also be acknowledged in future publications.

    keyboard with crowdfunding key instead of enter key

    Suggested contribution levels: $20/$50/$100



    Introduction

    Breast, colorectal, ovarian, and endometrial cancers constitute approximately 30% of newly diagnosed cancer cases in Switzerland, affecting more than 12,000 individuals annually [1]. About 2%-15% of incident cases are associated with known hereditary cancer syndromes. Several hundred Swiss patients diagnosed with any of these cancers are likely to carry known pathogenic germline variants [2]. Approximately 5-10% of breast cancer cases and 10%-15% of epithelial ovarian cancer cases develop due to single gene mutations that are passed down in the family, such as the breast cancer 1 (BRCA1) and breast cancer 2 (BRCA2) genes [3,4]. Germline BRCA mutations are associated with most hereditary breast and ovarian cancer (HBOC) cases. Women with BRCA mutations have a 55%-70% risk of breast cancer and 17%-59% risk of ovarian cancer by age 70, while the corresponding lifetime risks in the general population are 12% and 1.3%, respectively [5-7]. HBOC cases have an increased risk of cancer at a younger age, often before recommendations for routine screening apply [8,9]. The prevalence of BRCA mutations varies considerably among ethnic groups and geographical areas. In Caucasian populations, the prevalence of BRCA pathogenic variants is estimated at 1:400 to 1:500, whereas the frequency of three founder mutations in the Ashkenazi Jewish population is 1:40 [10-12]. About 21% of Swiss breast cancer patients are diagnosed younger than 50 years old, which may indicate genetic susceptibility [13,14].

    Lynch syndrome (LS), previously known as hereditary nonpolyposis colorectal cancer, is an inherited disorder, associated with 22%-74% lifetime risk for colorectal cancer, 14%-71% risk for endometrial cancer, 3%-22% risk for ovarian cancer, up to 13% risk for gastric cancer, and up to 25% risk for urothelial cancer [15]. LS accounts for about 2%-5% of colorectal cancer and endometrial cancer burden, as well as increased risk for several other malignancies including gastric, ovarian, small bowel, urinary and biliary tract, pancreatic, and sebaceous gland tumors [16]. Individuals with LS have a 10%-74% risk of colorectal cancer, and a 14%-71% risk of endometrial cancer by age 70, while the corresponding rates in the general population are 5.5% and 2.7%, respectively [17,18]. A hallmark of LS is early age of onset, usually before the age of 50 at which recommendations for routine screening apply [15,19]. Most LS-related tumors are characterized by a high level of microsatellite instability (MSI-H), which is distinctive of cancers with a defective DNA mismatch repair (MMR) mechanism [20]. Diagnosis of LS involves a sequential process including prescreening with MSI testing and immunohistochemistry analysis to determine expression of the main MMR proteins (MLH1, MSH2, MSH6, PMS2) in tumor tissues. Additional MLH1 promoter methylation testing eliminates the possibility of loss of MLH1 expression due to epigenetic mechanisms or identification of a somatic BRAF pathogenic variant (c.1799T>A/p.V600E). In the case of pathological prescreening results, germline analyses of two or more MMR genes (MLH1/PMS2 and/or MSH2/MSH6) and search for EPCAM deletions confirm the diagnosis. Germline mutations in the MLH1 and MSH2 genes account for up to 90% of LS cases, whereas MSH6 and PMS2 mutations account for most of the remaining cases [21]. The Amsterdam Criteria II and Revised Bethesda Guidelines are used in clinical practice for identifying individuals concerned about LS [22]. These guidelines are not sensitive enough and may miss up to 30% of LS cases [23]. Even if the population prevalence of LS is estimated at 1:440 [24], LS is vastly underdiagnosed compared to HBOC.

    Germline mutations connected to HBOC and LS are inherited in an autosomal dominant manner. De novo mutations are rare in these syndromes. For every identified mutation carrier, there are multiple family members who may carry the same mutation. First- and second-degree relatives and first cousins of known carriers have 50%, 25%, and 12.5% probability for inheriting the respective cancer predisposition. The availability of cancer genetic services (counseling and testing) for HBOC and LS is a significant milestone for effective cancer prevention and control [25]. When a pathogenic variant is identified, relatives can be tested with 100% accuracy [26]. Genetic counseling can educate patients and cancer-free individuals about cancer risk and management options according to mutation status. Physicians’ attitudes [27] and coverage of cost of tests and gene panels by health insurance influence whether genetic testing is performed or not [28].

    A Swiss study reported that about 11% of all breast cancer patients and 25% of those with a strong family history used genetic services [29]. These figures are lower for LS-related colorectal and endometrial cancer patients, suggesting that many Swiss mutation carriers and their family members may not benefit from advances in health care technology and medical diagnostics. HBOC and LS patients are at an increased risk of secondary cancers and can benefit from intensive surveillance, pharmacoprevention, or prophylactic surgery. Prophylactic surgery such as mastectomy, bilateral salpingo-oophorectomy, and hysterectomy should be discussed with women affected with HBOC or LS [30]. Subtotal colectomy can be considered for LS patients with colorectal cancer [18]. Family members who test positive benefit from high-risk management care starting at age 25-30, or 10 years before the earliest age of breast cancer onset in the family. This care can include annual breast magnetic resonance imaging, mammograms, pelvic ultrasound for women (HBOC) [31], and annual colonoscopy starting at age 20-25, or 2-5 years before the earliest age of colorectal cancer onset in the family, whichever comes first (LS) [15,18]. Implementing clinical recommendations and providing high-quality surveillance to patients during survivorship requires excellent coordination of health care services provided in high-risk clinics [32-35].

    Mutation carriers identified through complete genetic analyses are asked to communicate test results to relatives and encourage them to use genetic services. This process is highly variable from family to family, with less than 40% of high-risk relatives using genetic services, suggesting a lack of effective communication [36,37]. Lack of understanding of genetic information combined with family conflicts most likely inhibits disclosure of test results to relatives [38,39]. In Switzerland, the Federal Act on Human Genetic Testing (HGTA) is the legal regulation that directly applies to the clinical practice of genetic analysis. HGTA states that a physician is not allowed to disclose genetic test results to anyone except the tested individual or their legal representative. Results can be disclosed to family members, spouses, or partners only with the explicit consent of the tested individual. If the tested individual refuses to disclose this information, if they are deceased, have disappeared, or are unable to consent in the absence of an authorized delegate, the physician can seek help from the expert commission on professional confidentiality. The physician may apply to the appropriate cantonal authority to be released from the duty of professional secrecy if protecting the overriding interests of the family members, spouse, or partner requires that they receive this information. Cantonal authorities may also request an opinion from the Expert Commission for Human Genetic Testing [40]. Interventions designed to facilitate patient-provider and patient-family communication can enhance understanding of genetic information and facilitate the disclosure of test results from carriers to relatives and can contribute to more effective management of hereditary cancer. Several such interventions have been developed and tested in the United States [41-51] but should be adapted before they can be implemented in Switzerland, due to cultural and possibly legal differences.

    Cascade screening is the sequential process of identifying and testing blood relatives of a known mutation carrier to determine if additional individuals carry the pathogenic variant, and proposing preventive and other clinical management options to reduce morbidity and mortality [52]. Cascade screening also reassures non-carrier relatives and excludes them from intensive surveillance, making it cost-effective and contributing to personalized medicine [53]. The Centers for Disease Control and Prevention, Office for Public Health Genomics issued evidence-based recommendations justifying genetic testing in affected individuals and relatives when there is a known family history of HBOC or other BRCA-related cancers, LS-related colorectal cancer, or familial hypercholesterolemia (FH). These are Tier 1 genetic conditions suitable to promoting translation of scientific breakthroughs in genetics to public health [54]. There are currently no systematic efforts to apply cascade screening for Tier 1 genetic conditions among the general population in Europe apart from the Netherlands, which successfully implemented a cascade screening program for FH. The implementation of this pioneering public health program helped identify more than 28,000 asymptomatic cases [55] and provides proof-of-concept that cascade screening can be applied in other settings [56].

    Robust evidence from basic science and descriptive population-based studies in Switzerland support the necessity of cascade screening for HBOC and LS [57-67]. However, there are currently no interventions to translate this knowledge into public health. Researchers know little about the cancer status and surveillance behaviors of mutation carriers and their relatives, and their needs for psychosocial, patient-provider, and family communication support. This is especially important over time, as little is known about decisional regret associated with genetic testing, communication, and support after the pathogenic variant has been identified in some family members but not in others, as well as impact on quality of life. A better understanding is needed of the overall response of the Swiss health care system to mutation carriers’ needs for long-term coordination of cancer surveillance and prevention. Finally, there are no interventions culturally tailored for Swiss families and designed to enhance patient-provider and patient-family communication, coping, and provide decisional support.

    Establishing a registry with families harboring germline pathogenic variants associated with HBOC and LS and the collection of cancer surveillance and psychosocial data over time will greatly assist in finding sustainable solutions and developing cutting-edge interventions that optimize the health care system. However, establishing cascade screening for HBOC and LS and promoting interventions for communicating hereditary cancer risks pose several challenges at the medical and social level, requiring interprofessional collaboration with stakeholders from basic research, the health care system, and social science. In response to this challenge, the Swiss Cancer Genetic Predisposition Cascade Screening Consortium was assembled in 2015 with stakeholders from various disciplines (ie, basic science, epidemiology, medicine, nursing, psychology, public health, and sociology) to conduct the CASCADE study and examine the feasibility of establishing a family-based registry and a cohort with HBOC and LS mutation-harboring families.

    The specific aims of the CASCADE study are to (1) survey index cases with HBOC or LS from clinic-based genetic testing records and determine their current cancer status and surveillance practices, needs for coordination of medical care, psychosocial needs, patient-provider and patient-family communication, quality of life, and willingness to serve as advocates for cancer genetic services to blood relatives, (2) survey blood relatives identified from pedigrees or family history records of HBOC and LS index cases and determine their current cancer and mutation status, cancer surveillance practices, needs for coordination of medical care, barriers and facilitators to using cancer genetic services, psychosocial needs, patient-provider and patient-family communication, quality of life, and willingness to participate in a study designed to increase use of cancer genetic services, and (3) explore the influence of patient-provider communication about genetic cancer risk on patient-family communication and the acceptability of a family-based communication, coping, and decision support intervention with focus group(s) of mutation carriers and relatives.


    Methods

    Design

    CASCADE is a longitudinal study using surveys and focus groups, designed to elicit factors that enhance cascade genetic testing for HBOC and LS in Switzerland. The CASCADE study will contact known mutation carriers for HBOC and LS and systematically identify and contact their relatives to determine if they have had genetic testing, if they also carry the pathogenic variant, and how they manage their risk for hereditary cancer. Repeated observations are the optimal way for assessing these outcomes. The study will also use focus groups to examine the acceptability of a family communication, coping, and decision support intervention (Phase I). Table 1 presents a detailed description of assessments conducted for the study. The study protocol has been approved by the local ethics committee, while approval from ethics committees in other cantons is underway. The study will be carried out according to principles described in the Declaration of Helsinki and applicable Swiss laws and Swiss regulatory authority requirements.

    Setting

    This multicenter study involves contributions from oncology and genetic testing centers from three linguistic regions of Switzerland (German-, French-, and Italian-speaking). Medical directors of clinical sites are either co-principal investigators (co-PIs) or site co-investigators and will oversee recruitment procedures according to the study protocol. The PI will oversee the scientific integrity of the study, including recruitment, data collection, and data analyses. These findings will be compiled and communicated to clinical sites.

    Sample and Sample Size

    The CASCADE study targets individuals who have been identified through genetic testing as carrying a pathogenic germline variant associated either with HBOC or LS and their relatives (first- and second-degree, and first cousins). Textbox 1 describes applicable inclusion and exclusion criteria. Index cases include male and female cancer patients and cancer-free individuals. Cancer risk associated with HBOC and LS does not apply to children, thus, the study will include only adults (≥18 years old). Decisions to undergo genetic testing for these conditions are made by adults deemed competent to provide informed consent and should be undertaken after individuals participate in consultation regarding the benefits and drawbacks of genetic testing. Vulnerable participants (eg, those living in nursing homes) will be excluded because they may not be able to consent to genetic testing or follow recommended cancer surveillance or preventive measures. Critically ill patients will be excluded from recruiting relatives and from focus groups to avoid increasing subject burden.

    Table 1. Flow of assessments for the CASCADE study.
    View this table

    Textbox 1. Characteristics of the target populations.
    View this box
    Figure 1. Expected recruitment of index cases.
    View this figure

    Estimates of sample size are based on the PI’s experience, consultations with medical directors of clinical sites, and assuming average prevalence rates of 5% for hereditary breast cancer and 2-5% for hereditary colorectal cancer (the two most common manifestations of HBOC and LS), respectively. Assuming that is feasible to recruit 10% of mutation carriers from each participating clinic, 300 index cases will be targeted for inclusion within 12 months. It is expected that around 70% of approached index cases will accept participation, meaning that 495 index cases need to be approached to reach 305. It is estimated that from each index case we will identify 2.5 relatives. Assuming a response rate of 50% among relatives, we expect to recruit approximately 381 relatives. Figure 1 presents the CONSORT [68] diagram for recruitment of expected index cases and relatives.

    Recruitment Procedures for Index Cases

    Participating Swiss clinical sites will record the total number of mutation-harboring families for HBOC or LS. A dedicated staff person at each clinical site, the site coordinator, will identify eligible index cases (ie, first person in the family identified as carrying a germline pathogenic variant associated with HBOC or LS), determine whether they can be contacted or not, and initiate and monitor the recruitment process. Selection of mutation-harboring families from each clinical site will involve the following steps:

    1. Each site creates a list with IDs (eg, 001…, 350) corresponding to each index case and a family with a pathogenic variant.
    2. The ID list is sent to the PI, who selects approximately 35% of cases with the assistance of a computer-generated random list. Identifiable information is not released until the index case accepts participation through signing an informed consent form.
    3. Site coordinators retrieve the medical charts of selected index cases and decide whether the cases can be contacted by determining living status and residence.
    4. If the index case is not available, then site coordinators identify first-degree relatives, who have also been identified through genetic testing as carriers of the familial pathogenic variant, and randomly (computer-generated list) select one of them.
    5. Steps 3 and 4 are repeated until an index case who can be the initial contact person for the family is identified. If this process yields no results, the next family is selected.
    6. All information obtained from each step is recorded, including minimum information for index cases. Minimum information includes demographics (age, gender), clinical history (tumor type, age at diagnosis, stage), and genetic testing results (including MSI and IHC tumor testing for LS patients) and is obtained from medical records. Index cases are recruited to the CASCADE study by the medical director of the respective site.

    Index cases will be mailed an information letter, two copies of the informed consent form, two copies of a participation refusal form, and a stamped self-addressed envelope to return their response to the clinical site. Index cases will be informed about the objectives of the CASCADE study, participation requirements, the study plan, confidentiality, and associated risk and benefits through the informed consent form, which explicitly requires their agreement to (1) complete the CASCADE survey, (2) contact one or more of their blood relatives for the study, (3) be contacted once a year for 5 years and provide updated information about their health, and (4) participate alone or with a blood relative in a focus group. Index cases can participate in all or in some of the above study steps. The information letter explains that the minimum requirement for taking part in the CASCADE study is to complete the self-administered survey once. The refusal form asks nonparticipating index cases the reason for their refusal; this information is necessary for the validity of the study.

    Site coordinators will determine whether the identified index case can be contacted or not by investigating whether they are alive and whether they live in Switzerland through hospital and civil records. If the recruitment package is returned undelivered, additional address verification methods will be used to locate a new residence. If the index case cannot be contacted a priori, coordinators will determine whether a first-degree relative can be the new index case for the family. Three attempts will be made to contact index cases for each family. If the study receives no response 6 weeks after the third attempt, a new family will be selected to preserve required sample size. Index cases will be recruited to the CASCADE study on a consecutive ongoing basis. Site coordinators will review pedigrees and family history of index cases who accept participation to extract demographic and medical information and to record all blood relatives (first- and second-degree relatives and first cousins). Index cases will be asked to complete a self-administered survey.

    When an index case has not received genetic counseling at the participating center, the invitation package for the CASCADE study will be sent by the referring physician. This is necessary because some clinical sites perform only genetic testing and the referring physician is considered the medical person who has direct knowledge of index case’s genetic testing results. Site coordinators and the PI will keep track of the recruitment process. Referring physicians will make three recruitment attempts by mailing a new invitation package every 6 weeks if the index case does not respond to the invitation (either positively or negatively). Contact information (address, telephone, email) of the PI and the medical director will be provided in the information letter, so that index cases can request further information about the study at any point. A signed informed consent will be requested prior to index case’s enrollment as a prerequisite for engagement in the CASCADE study.

    Recruitment Procedures for Relatives

    In order to alleviate ethical concerns associated with contacting blood relatives (ie, first- and second-degree relatives, and first cousins) without their explicit consent, the CASCADE study will approach them through index cases and will approach only relatives the index case is willing to contact. This recruitment method has been used in previous family-based studies with very good recruitment outcomes [69,70]. Index cases will be mailed recruitment packages to pass on to their relatives, including an information letter, two copies of the informed consent form, two copies of the participation refusal form, and a stamped self-addressed envelope for relatives to return their response to the PI. Relatives’ identifiable information will not be released to the PI. By returning a signed informed consent, the relative indicates willingness to participate and releases their identifiable information to the PI. Once this information is available, a recruiter will contact them to ascertain eligibility. If relatives do not respond after 6 weeks, the PI will contact the index case asking them to pass on a reminder letter to the nonresponding relative. If this effort yields no response, there will be no further attempts to contact the relative. Relatives agreeing to participate will receive a similar survey as the index case, asking if they are willing to (1) invite additional relatives to the CASCADE study, (2) be contacted once a year for 5 years and provide updated information about their health, and (3) participate alone or with a blood relative in a focus group. Relatives can also participate in all or some of the above study steps.

    Recruitment Procedures for Focus Groups

    Two series of focus groups will be organized to explore the (1) difficulties associated with patient-provider communication regarding genetic cancer risk, (2) difficulties associated with patient-family communication regarding the pathogenic mutation, (3) mutual influence of patient-provider and patient-family communication, and (4) acceptability of a family-based intervention designed to enhance communication, coping, and decision making for genetic testing. A purposeful sample of index cases and relatives will be selected from individuals who agreed to participate in focus groups. The sampling method will be based on the expertise of the qualitative methodologist from interviews with Swiss BRCA carriers [32,33,71] and the PI’s experience conducting focus groups with US BRCA families. Segmentation strategy will guide sampling methods and the composition of the focus groups. Each focus group will be relatively homogeneous, while the full set will include several potentially distinct perspectives [72]. Focus groups will include 5-10 participants. Male and female cancer patients and cancer-free individuals will be selected to represent HBOC and LS.

    It is expected that data saturation will be reached with 6-10 focus groups including about 30-60 carriers and 30-60 relatives. The first series of focus groups will include only mutation carriers stratified according to level of family communication (high, intermediate, low). These focus groups will explore the difficulties in patient-provider and patient-family communication, and the interrelatedness of these two types of communication. The second series of focus groups will include carriers and relatives and will explore the acceptability of an intervention designed to facilitate communication of test results among family members, helpful coping mechanisms, and decision making for genetic testing. Two sampling methods are envisioned. One method involves several members of the same family who can be invited together; the other involves 3-4 family pairs consisting of one carrier and one relative, which will be homogeneous in terms of gender, health status, etc. The sampling method of the second series of focus groups will be informed by responses to the CASCADE survey and findings from the first series of focus groups.

    Data Collection and Data Management

    The CASCADE survey will be developed in English, translated into three languages (German, French, and Italian), and back-translated into English by professional translators, except for scales with validated versions in these languages (eg, 12-Item Short Form Health Survey [SF-12]). Discrepancies will be resolved by the PI with the collaboration of the translators and the co-investigators. Index cases and relatives will be given the choice to complete the CASCADE survey either as paper/pencil or using an online platform. The content of the paper/pencil and online survey are identical. Participants who choose to complete the survey online will receive an access code and will be instructed how to log into a secure Web platform. If a survey is missing important information (eg, number of relatives the index case is willing to contact), research personnel will contact participants to ascertain it.

    No identifying information, such as name and address, is collected with paper/pencil or online surveys. Each index case is given a code; for example, G001-IC stands for an index case selected from the Geneva clinic with the family study code 001. Relatives recruited from this index case will be coded G001-R1, G001-R2, etc, to establish the link between family members. This code will be used for surveys, consent forms, refusal forms, and correspondence letters to match participants to the correct family unit and maintain the study’s internal validity. The PI and coordinators will keep logs with these codes. The coding key will be kept in a password-protected computer file and will be available to the PI, members of the Swiss Cancer Genetic Predisposition Cascade Screening Consortium, and key personnel. The code will be broken only to avert an immediate risk to the health of the person, in cases of withdrawal from the study, or when there is a legal basis.

    All study data will be collected and stored in a secure database and handled by the data management team from the Clinical Trials Unit, University Hospital, Basel (CTU Basel). The online survey will be implemented using LimeSurvey, installed on a separate server, and exclusively used for the study. Lime Survey is an established app to perform online surveys. The system (server and data) is integrated in a regular backup process. Data transfer from and to the Web-based survey system are encrypted using secure sockets layer/transport layer security (SSL/TLS). The secure database will be used for data collection and to track returned surveys. Data entered for paper/pencil surveys will be double-checked for accuracy. The usability of the paper/pencil or online survey will be assessed based on number of individuals who choose either mode, percent of missing data, etc. Many items are parts of multi-item scales and are anticipated to correlate with each other. The reliability of these scales will be tested using principal component analyses and Cronbach alpha coefficients. Scales with alpha≥.71 will be used. On completion of approximately 30 surveys, scale psychometrics will be examined. For any given scale that shows less than required psychometric properties (ie, Cronbach alpha<.71 and factor analysis indicates item loadings <10% compared to item loadings in the original scale), a revision of the translated scale will be undertaken. This will allow comparisons of scale reliability based on delivery mode and will establish whether the survey can be administered interchangeably.

    Health-related and personal data collected for the CASCADE study are confidential; coding will safeguard participants’ confidentiality. All study documents will be archived in the PI’s office. Site-related documents will be archived at the office of each medical director. Administrative data are accessible only by authorized personnel and data managers from CTU Basel. Direct access to documents will be permitted for monitoring, audits, or inspections. Ethics committee members, members of the Swiss Cancer Genetic Predisposition Cascade Screening Consortium, the statistician, and key personnel will have access to project plan, dataset, statistical code, etc, during and after the study (publication, dissemination). Paper/pencil surveys will be stored in a separate research office in the PI’s building for 5 years and then destroyed by shredding. Once all data have been collected, the complete dataset and survey setup will be exported by CTU Basel and transferred to the PI and the statistician via a secure channel. The survey system (including database) will be purged after the end of the study. The PI will archive the electronic data for a minimum of 10 years.

    Outcomes

    Table 2 [73-89] describes primary outcomes for index cases and relatives and the scales used to assess them. The feasibility of establishing a family-based registry will be assessed using the number of mutation-harboring families associated with HBOC and LS from each clinical site, the number of relatives identified from pedigrees and family history, index cases’ response rate to the CASCADE survey, the number of relatives each index case is willing to invite, relatives’ response rate to the CASCADE survey, and the willingness of index cases and relatives to be contacted once a year for 5 years. Additional outcomes include assessing acceptance rates of paper/pencil and online platform and quality of data (eg, percent missing values).

    Table 2. Scales used in the CASCADE survey.
    View this table

    Data Analyses

    Selection bias will be minimized by random selection of mutation-harboring families in each clinical site from three linguistic regions of Switzerland. Stratification will ensure selection of an equal proportion of index cases from clinical sites that offer genetic services for both syndromes. The study will try to recruit all index cases from clinical sites including fewer than 100 mutation-harboring HBOC/LS families to ensure a representative sample.

    All statistical analyses will be conducted in licensed software packages, including Microsoft Excel, SPSS (IBM), and R. For all statistical tests, significance will be set at two-sided alpha=.05. Data values will be examined for legality (within appropriate range) using histograms and box plots and corrected when possible. Descriptive analyses will include calculating means, standard deviations, frequencies, and percentages of variables and participant descriptors. Bivariate analyses (Pearson correlations, chi-square test for differences in proportions, and t test for differences in means) will assess associations between demographics and clinical characteristics. Regression analyses will incorporate generalized estimating equations for pairing index cases with their relatives and explore to what extent predictors are in direct, mediating, or moderating relationship to an outcome.

    The following comparisons will take place: between index cases and relatives, between HBOC and LS, between men and women, cancer patients versus cancer-free individuals, participants with children versus those with no children, between different age groups and different cancer diagnoses. Data from participants who withdraw will be kept in the study to ensure the internal validity of the study. Missing data from multi-item scales will be addressed with multiple imputations using R software if they exceed 5% of observations and if they are less than 25% for each specific scale. Scale reliability will be assessed with Cronbach alpha and principle component analyses. Deviations from the planned analyses are not foreseen. The study statistician will review and approve any deviations from the original statistical plan if necessary.

    Narrative data from focus groups will be recorded and transcribed verbatim to allow data management and content examination. Thematic analyses to inductively classify data in concepts and categories, as these emerge through an interpretive process, will be carried out under the guidance of the qualitative methodologist [90]. Focus group participants will be shown a prototype of a family-based intervention as a PowerPoint presentation. Then they will be asked if they like the intervention, if they find it useful, and how it can be improved. Acceptability of the intervention will be assessed with a short survey using 7-point Likert-type items (1=Low to 7=High) asking overall satisfaction with the content, format and appearance of the program, and whether it can help with family communication, coping, and decision making. The survey assesses six acceptability items: ease of use, clarity, appropriate length, appropriate level of detail, able to hold interest, and satisfaction.


    Results

    This study is currently recruiting participants.


    Discussion

    Principal Considerations

    Cancer predisposition cascade genetic screening combines personalized medicine and public health. Once a mutation carrier for HBOC or Lynch syndrome is identified, evidence-based interventions are available that can reduce the risk of adverse health outcomes in entire cohorts of relatives [91]. This approach is cost-effective for Tier 1 genetic conditions, leading to reduced medical and insurance coverage costs (eg, treatment and hospitalization expenses) [92-94]. Cascade screening for FH applied in the Netherlands identified thousands of mutation carriers for the disorder and has been subsidized by the Dutch government since 2015 [95,96]. Similar programs for FH have also been implemented in Scotland and Wales [97,98].

    Availability of genetic testing created an increasing demand for coordination of health care services and risk communication among index cases and relatives. Knowledge of hereditary risk can serve as an information tool to reduce cancer morbidity and mortality. This necessitates the establishment of family-based registries that systematically record genetic information. Currently, this information is fragmented and dispersed across Swiss clinical sites. The establishment of high-risk clinics would allow synergistic approaches in cancer surveillance and medical care offered to these families. Effective data sharing and dissemination across disciplines is mandatory for increasing the impact of genetic screening, ensure resource allocation, and facilitate health care policy and decision making.

    Conclusion

    CASCADE study will promote multidisciplinary research in public health genetics at the cutting edge of medicine with strong translational application. This has significant potential to enhance the development of high-quality comprehensive support systems to improve use of cancer genetic services and facilitate patient involvement in health care decisions. The long-term outcome of this program is the development and implementation of new models for systematic surveillance and detection of individuals at risk for hereditary cancer in Switzerland. Immediate outcomes are the assessment of current use of cancer genetic services and evaluation of the public health impact of HBOC and LS. The CASCADE study will document the needs of mutation-harboring families, including barriers and facilitators to accessing cancer genetic services, and will promote use of family history for genetic risk assessment. The study will also provide information for the acceptability of an intervention that will potentially increase genetic literacy, expand understanding of health care technologies, and reduce HBOC- and LS-related morbidity and mortality in Switzerland.

    Acknowledgments

    Funding for this study was provided by the University of Basel, Forschungsfonds in March 2016 to MK.

    Conflicts of Interest

    None declared.

    References

    1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015 Mar 01;136(5):E359-E386 [FREE Full text] [CrossRef] [Medline]
    2. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang X, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2015 Mar 14;385(9972):977-1010 [FREE Full text] [CrossRef] [Medline]
    3. Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003 May;72(5):1117-1130 [FREE Full text] [CrossRef] [Medline]
    4. Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A 2011 Nov 01;108(44):18032-18037 [FREE Full text] [CrossRef] [Medline]
    5. Couch FJ, Nathanson KL, Offit K. Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science 2014 Mar 28;343(6178):1466-1470 [FREE Full text] [CrossRef] [Medline]
    6. Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, EMBRACE. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013 Jun 05;105(11):812-822. [CrossRef] [Medline]
    7. NCI SEER Data, 1973-2014, 1973-2014. 2017 May 17.   URL: https://seer.cancer.gov/data/ [accessed 2017-05-17] [WebCite Cache]
    8. Balmaña J, Díez O, Rubio IT, Cardoso F, ESMO Guidelines Working Group. BRCA in breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2011 Sep;22 Suppl 6:vi31-vi34. [CrossRef] [Medline]
    9. Christinat A, Pagani O. Practical aspects of genetic counseling in breast cancer: lights and shadows. Breast 2013 Aug;22(4):375-382. [CrossRef] [Medline]
    10. Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 2000 Nov;83(10):1301-1308 [FREE Full text] [CrossRef] [Medline]
    11. King M, Marks JH, Mandell JB, New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003 Oct 24;302(5645):643-646 [FREE Full text] [CrossRef] [Medline]
    12. Whittemore AS, Gong G, John EM, McGuire V, Li FP, Ostrow KL, et al. Prevalence of BRCA1 mutation carriers among U.S. non-Hispanic Whites. Cancer Epidemiol Biomarkers Prev 2004 Dec;13(12):2078-2083 [FREE Full text] [Medline]
    13. Bouchardy C, Lorez M, Arndt V. Schweizer Krebsbulletin; 35 (Auflage 4200). 2015 Jun 15. Effects of age and stage on breast cancer survival in Switzerland   URL: http://www.zora.uzh.ch/id/eprint/117137/ [accessed 2017-08-31] [WebCite Cache]
    14. Schoumacher F, Glaus A, Mueller H, Eppenberger U, Bolliger B, Senn HJ. BRCA1/2 mutations in Swiss patients with familial or early-onset breast and ovarian cancer. Swiss Med Wkly 2001 Apr 21;131(15-16):223-226. [Medline]
    15. Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on colorectal cancer. Am J Gastroenterol 2014 Aug;109(8):1159-1179. [CrossRef] [Medline]
    16. Bonis P, Trikalinos T, Chung M, Chew P, Ip S, DeVine D, et al. Hereditary nonpolyposis colorectal cancer: diagnostic strategies and their implications. Evid Rep Technol Assess (Full Rep) 2007 May(150):1-180. [Medline]
    17. Bellcross CA, Bedrosian SR, Daniels E, Duquette D, Hampel H, Jasperson K, et al. Implementing screening for Lynch syndrome among patients with newly diagnosed colorectal cancer: summary of a public health/clinical collaborative meeting. Genet Med 2012 Jan;14(1):152-162 [FREE Full text] [CrossRef] [Medline]
    18. Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 2015 Feb;110(2):223-262; quiz 263 [FREE Full text] [CrossRef] [Medline]
    19. US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW, et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2016 Jun 21;315(23):2564-2575. [CrossRef] [Medline]
    20. Kladny J, Lubinski J. Lynch syndrome (HNPCC). Hered Cancer Clin Pract 2008 Jun 15;6(2):99-102 [FREE Full text] [CrossRef] [Medline]
    21. Lynch HT, Snyder CL, Shaw TG, Heinen CD, Hitchins MP. Milestones of Lynch syndrome: 1895-2015. Nat Rev Cancer 2015 Dec;15(3):181-194. [CrossRef] [Medline]
    22. Umar A, Boland CR, Terdiman JP, Syngal S, de LCA, Rüschoff J, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004 Feb 18;96(4):261-268 [FREE Full text] [Medline]
    23. Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 2009 Jan;11(1):42-65 [FREE Full text] [CrossRef] [Medline]
    24. Chen S, Wang W, Lee S, Nafa K, Lee J, Romans K, Colon Cancer Family Registry. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA 2006 Sep 27;296(12):1479-1487 [FREE Full text] [CrossRef] [Medline]
    25. Kalady MF, Heald B. Diagnostic Approach to Hereditary Colorectal Cancer Syndromes. Clin Colon Rectal Surg 2015 Dec;28(4):205-214 [FREE Full text] [CrossRef] [Medline]
    26. Lynch JA, Venne V, Berse B. Genetic tests to identify risk for breast cancer. Semin Oncol Nurs 2015 May;31(2):100-107 [FREE Full text] [CrossRef] [Medline]
    27. Douma KFL, Meiser B, Kirk J, Mitchell G, Saunders C, Rahman B, et al. Health professionals' evaluation of delivering treatment-focused genetic testing to women newly diagnosed with breast cancer. Fam Cancer 2015 Jun;14(2):265-272. [CrossRef] [Medline]
    28. Clain E, Trosman JR, Douglas MP, Weldon CB, Phillips KA. Availability and payer coverage of BRCA1/2 tests and gene panels. Nat Biotechnol 2015 Sep;33(9):900-902 [FREE Full text] [CrossRef] [Medline]
    29. Ayme A, Viassolo V, Rapiti E, Fioretta G, Schubert H, Bouchardy C, et al. Determinants of genetic counseling uptake and its impact on breast cancer outcome: a population-based study. Breast Cancer Res Treat 2014 Apr;144(2):379-389. [CrossRef] [Medline]
    30. Schmeler KM, Lynch HT, Chen L, Munsell MF, Soliman PT, Clark MB, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006 Jan 19;354(3):261-269. [CrossRef] [Medline]
    31. Le-Petross HT, Whitman GJ, Atchley DP, Yuan Y, Gutierrez-Barrera A, Hortobagyi GN, et al. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer. Cancer 2011 Sep 01;117(17):3900-3907 [FREE Full text] [CrossRef] [Medline]
    32. Caiata-Zufferey M. Genetically at-risk status and individual agency. A qualitative study on asymptomatic women living with genetic risk of breast/ovarian cancer. Soc Sci Med 2015 May;132:141-148. [CrossRef] [Medline]
    33. Caiata-Zufferey M, Pagani O, Cina V, Membrez V, Taborelli M, Unger S, et al. Challenges in managing genetic cancer risk: a long-term qualitative study of unaffected women carrying BRCA1/BRCA2 mutations. Genet Med 2015 Sep;17(9):726-732. [CrossRef] [Medline]
    34. Howell D, Hack TF, Oliver TK, Chulak T, Mayo S, Aubin M, et al. Models of care for post-treatment follow-up of adult cancer survivors: a systematic review and quality appraisal of the evidence. J Cancer Surviv 2012 Dec;6(4):359-371. [CrossRef] [Medline]
    35. IOM. Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis. Washington, DC: National Academies Press; 2013.   URL: http:/​/www.​nationalacademies.org/​hmd/​~/​media/​Files/​Report%20Files/​2013/​Quality-Cancer-Care/​qualitycancercare_rb.​pdf [accessed 2017-09-07] [WebCite Cache]
    36. Blandy C, Chabal F, Stoppa-Lyonnet D, Julian-Reynier C. Testing participation in BRCA1/2-positive families: initiator role of index cases. Genet Test 2003;7(3):225-233. [CrossRef] [Medline]
    37. Suthers GK, Armstrong J, McCormack J, Trott D. Letting the family know: balancing ethics and effectiveness when notifying relatives about genetic testing for a familial disorder. J Med Genet 2006 Aug;43(8):665-670 [FREE Full text] [CrossRef] [Medline]
    38. Gurmankin AD, Domchek S, Stopfer J, Fels C, Armstrong K. Patients' resistance to risk information in genetic counseling for BRCA1/2. Arch Intern Med 2005 Mar 14;165(5):523-529. [CrossRef] [Medline]
    39. Tercyak KP, Demarco TA, Mars BD, Peshkin BN. Women's satisfaction with genetic counseling for hereditary breast-ovarian cancer: psychological aspects. Am J Med Genet A 2004 Nov 15;131(1):36-41 [FREE Full text] [CrossRef] [Medline]
    40. Federal Act on Human Genetic Testing.   URL: https://www.admin.ch/opc/en/classified-compilation/20011087/201401010000/810.12.pdf [accessed 2017-09-08] [WebCite Cache]
    41. Dekker N, Hermens RPMG, Elwyn G, van DWT, Nagengast FM, van DP, et al. Improving calculation, interpretation and communication of familial colorectal cancer risk: protocol for a randomized controlled trial. Implement Sci 2010 Jan 28;5:6 [FREE Full text] [CrossRef] [Medline]
    42. Graves K, Wenzel L, Schwartz M, Luta G, Wileyto P, Narod S, et al. Randomized controlled trial of a psychosocial telephone counseling intervention in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2010 Mar;19(3):648-654 [FREE Full text] [CrossRef] [Medline]
    43. Green MJ, Peterson SK, Baker MW, Harper GR, Friedman LC, Rubinstein WS, et al. Effect of a computer-based decision aid on knowledge, perceptions, and intentions about genetic testing for breast cancer susceptibility: a randomized controlled trial. JAMA 2004 Jul 28;292(4):442-452 [FREE Full text] [CrossRef] [Medline]
    44. Hooker GW, Leventhal K, DeMarco T, Peshkin BN, Finch C, Wahl E, et al. Longitudinal changes in patient distress following interactive decision aid use among BRCA1/2 carriers: a randomized trial. Med Decis Making 2011;31(3):412-421 [FREE Full text] [CrossRef] [Medline]
    45. Joseph G, Beattie MS, Lee R, Braithwaite D, Wilcox C, Metrikin M, et al. Pre-counseling Education for Low Literacy Women at Risk of Hereditary Breast and Ovarian Cancer (HBOC): Patient Experiences Using the Cancer Risk Education Intervention Tool (CREdIT). J Genet Counsel 2010 May 19;19(5):447-462. [CrossRef]
    46. Kaphingst KA, Persky S, McCall C, Lachance C, Loewenstein J, Beall AC, et al. Testing the effects of educational strategies on comprehension of a genomic concept using virtual reality technology. Patient Educ Couns 2009 Nov;77(2):224-230 [FREE Full text] [CrossRef] [Medline]
    47. Kardashian A, Fehniger J, Creasman J, Cheung E, Beattie MS. A Pilot study of the Sharing Risk Information Tool (ShaRIT) for Families with Hereditary Breast and Ovarian Cancer Syndrome. Hered Cancer Clin Pract 2012 Apr 12;10(1):4 [FREE Full text] [CrossRef] [Medline]
    48. Mancini J, Noguès C, Adenis C, Berthet P, Bonadona V, Chompret A, et al. Impact of an information booklet on satisfaction and decision-making about BRCA genetic testing. Eur J Cancer 2006 May;42(7):871-881. [CrossRef] [Medline]
    49. Tiller K, Meiser B, Gaff C, Kirk J, Dudding T, Phillips K, et al. A randomized controlled trial of a decision aid for women at increased risk of ovarian cancer. Med Decis Making 2006;26(4):360-372. [CrossRef] [Medline]
    50. Wakefield CE, Meiser B, Homewood J, Peate M, Taylor A, Lobb E, AGenDA Collaborative Group. A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer risk. Breast Cancer Res Treat 2008 Jan;107(2):289-301. [CrossRef] [Medline]
    51. Wang C, Gonzalez R, Milliron KJ, Strecher VJ, Merajver SD. Genetic counseling for BRCA1/2: a randomized controlled trial of two strategies to facilitate the education and counseling process. Am J Med Genet A 2005 Apr 01;134A(1):66-73. [CrossRef] [Medline]
    52. Grosse SD, Rogowski WH, Ross LF, Cornel MC, Dondorp WJ, Khoury MJ. Population screening for genetic disorders in the 21st century: evidence, economics, and ethics. Public Health Genomics 2010;13(2):106-115. [CrossRef] [Medline]
    53. Hampel H. Genetic counseling and cascade genetic testing in Lynch syndrome. Fam Cancer 2016 Jul;15(3):423-427. [CrossRef] [Medline]
    54. Khoury MJ, Evans JP. A public health perspective on a national precision medicine cohort: balancing long-term knowledge generation with early health benefit. JAMA 2015 Jun 02;313(21):2117-2118 [FREE Full text] [CrossRef] [Medline]
    55. Galema-Boers JMH, Versmissen J, Roeters VLHWO, Dusault-Wijkstra JE, Williams M, Roeters VLJE. Cascade screening of familial hypercholesterolemia must go on. Atherosclerosis 2015 Oct;242(2):415-417. [CrossRef] [Medline]
    56. Samimi G, Bernardini MQ, Brody LC, Caga-Anan CF, Campbell IG, Chenevix-Trench G, et al. Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach. J Clin Oncol 2017 Jul 10;35(20):2329-2337. [CrossRef] [Medline]
    57. Bouchardy C, Benhamou S, Fioretta G, Verkooijen HM, Chappuis PO, Neyroud-Caspar I, et al. Risk of second breast cancer according to estrogen receptor status and family history. Breast Cancer Res Treat 2011 May;127(1):233-241. [CrossRef] [Medline]
    58. Buehler M, Tse B, Leboucq A, Jacob F, Caduff R, Fink D, et al. Meta-analysis of microarray data identifies GAS6 expression as an independent predictor of poor survival in ovarian cancer. Biomed Res Int 2013;2013:238284 [FREE Full text] [CrossRef] [Medline]
    59. Decollogne S, Joshi S, Chung SA, Luk PP, Yeo RX, Nixdorf S, et al. Alterations in the mitochondrial responses to PENAO as a mechanism of resistance in ovarian cancer cells. Gynecol Oncol 2015 Aug;138(2):363-371. [CrossRef] [Medline]
    60. Genevay M, Benusiglio PR, Hutter P, Chappuis PO. [Lynch syndrome: when pathologist and clinician have the opportunity to reduce the risk of developing cancer]. Rev Med Suisse 2011 Jul 27;7(303):1502-1506. [Medline]
    61. Heinimann K. Toward a molecular classification of colorectal cancer: the role of microsatellite instability status. Front Oncol 2013 Oct 31;3:272 [FREE Full text] [CrossRef] [Medline]
    62. Henry C, Llamosas E, Knipprath-Meszaros A, Schoetzau A, Obermann E, Fuenfschilling M, et al. Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion. Oncotarget 2015 Nov 24;6(37):40310-40326 [FREE Full text] [CrossRef] [Medline]
    63. Kempers MJE, Kuiper RP, Ockeloen CW, Chappuis PO, Hutter P, Rahner N, et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol 2011 Jan;12(1):49-55 [FREE Full text] [CrossRef] [Medline]
    64. Manegold-Brauer G, Bellin AK, Tercanli S, Lapaire O, Heinzelmann-Schwarz V. The special role of ultrasound for screening, staging and surveillance of malignant ovarian tumors: distinction from other methods of diagnostic imaging. Arch Gynecol Obstet 2014 Mar;289(3):491-498. [CrossRef] [Medline]
    65. Schwab FD, Bürki N, Huang DJ, Heinzelmann-Schwarz V, Schmid SM, Vetter M, et al. Impact of breast cancer family history on tumor detection and tumor size in women newly-diagnosed with invasive breast cancer. Fam Cancer 2014 Mar;13(1):99-107. [CrossRef] [Medline]
    66. Vasen HFA, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, Mallorca Group. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 2013 Jun;62(6):812-823 [FREE Full text] [CrossRef] [Medline]
    67. Verkooijen HM, Rapiti E, Fioretta G, Vinh-Hung V, Keller J, Benhamou S, et al. Impact of a positive family history on diagnosis, management, and survival of breast cancer: different effects across socio-economic groups. Cancer Causes Control 2009 Nov;20(9):1689-1696. [CrossRef] [Medline]
    68. Eysenbach G, CONSORT-EHEALTH Group. CONSORT-EHEALTH: improving and standardizing evaluation reports of Web-based and mobile health interventions. J Med Internet Res 2011 Dec 31;13(4):e126 [FREE Full text] [CrossRef] [Medline]
    69. Katapodi MC, Duquette D, Yang JJ, Mendelsohn-Victor K, Anderson B, Nikolaidis C, et al. Recruiting families at risk for hereditary breast and ovarian cancer from a statewide cancer registry: a methodological study. Cancer Causes Control 2017 Mar;28(3):191-201. [CrossRef] [Medline]
    70. Katapodi MC, Northouse LL, Milliron KJ, Liu G, Merajver SD. Individual and family characteristics associated with BRCA1/2 genetic testing in high-risk families. Psychooncology 2013 Jun;22(6):1336-1343. [CrossRef] [Medline]
    71. Caiata-Zufferey M, Schulz PJ. Physicians' communicative strategies in interacting with Internet-informed patients: results from a qualitative study. Health Commun 2012;27(8):738-749. [CrossRef] [Medline]
    72. Morgan D, Krueger R, King J. Focus Group Kit. Thousand Oaks, CA: SAGE Publications; 1998.
    73. Katapodi M, Northouse L, Schafenacker A, Duquette D, Duffy S, Ronis D, et al. Using a state cancer registry to recruit young breast cancer survivors and high-risk relatives: protocol of a randomized trial testing the efficacy of a targeted versus a tailored intervention to increase breast cancer screening. BMC Cancer 2013 Mar 1;13(1):e1001940 [FREE Full text] [CrossRef]
    74. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989 Dec 20;81(24):1879-1886. [Medline]
    75. Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 2001 Mar 07;93(5):358-366. [Medline]
    76. Michigan Department of Health and Human Services. BRFS annual questionnaires. 2017.   URL: http://www.michigan.gov/mdhhs/0,5885,7-339-71550_5104_5279_39424_39425-263911--,00.html [accessed 2017-08-31] [WebCite Cache]
    77. Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol 2016 Feb 20;34(6):611-635. [CrossRef] [Medline]
    78. Vickberg SMJ. The Concerns About Recurrence Scale (CARS): a systematic measure of women's fears about the possibility of breast cancer recurrence. Ann Behav Med 2003;25(1):16-24. [Medline]
    79. Katapodi M, Jung M, Milliron K, Merajver S, Northouse L. Psychological distress of developing hereditary breast/ovarian cancer among female relatives who did not pursue BRCA1 or BRCA2 genetic testing. 2009 Presented at: 11th International Conference on Psychosocial Aspects of Genetic Testing for Hereditary Cancer; April 5, 2009; Toronto, ON p. 23-22.
    80. Katapodi MC, Munro ML, Pierce PF, Williams RA. Psychometric testing of the decisional conflict scale: genetic testing hereditary breast and ovarian cancer. Nurs Res 2011;60(6):368-377 [FREE Full text] [CrossRef] [Medline]
    81. Brehaut JC, O'Connor AM, Wood TJ, Hack TF, Siminoff L, Gordon E, et al. Validation of a decision regret scale. Med Decis Making 2003;23(4):281-292. [CrossRef] [Medline]
    82. Carver CS. You want to measure coping but your protocol's too long: consider the brief COPE. Int J Behav Med 1997;4(1):92-100. [CrossRef] [Medline]
    83. Bandura A. Human agency in social cognitive theory. Am Psychol 1989 Sep;44(9):1175-1184. [Medline]
    84. Katapodi MC, Aouizerat BE. Do women in the community recognize hereditary and sporadic breast cancer risk factors? Oncol Nurs Forum 2005 May 10;32(3):617-623. [CrossRef] [Medline]
    85. Katapodi MC, DeFlon SL, Milliron KJ, Northouse LL, Merajver S. Knowledge of risk factors and modes of gene transmission among women at risk for hereditary breast and ovarian cancer syndrome. JCO 2011 May 20;29(15_suppl):e12017. [CrossRef]
    86. Lewis FM, Hammond MA, Woods NF. The family's functioning with newly diagnosed breast cancer in the mother: the development of an explanatory model. J Behav Med 1993 Aug;16(4):351-370. [Medline]
    87. Katapodi MC, Facione NC, Miaskowski C, Dodd MJ, Waters C. The influence of social support on breast cancer screening in a multicultural community sample. Oncol Nurs Forum 2002 Jun;29(5):845-852. [CrossRef] [Medline]
    88. Anderson B, McLosky J, Wasilevich E, Lyon-Callo S, Duquette D, Copeland G. Barriers and facilitators for utilization of genetic counseling and risk assessment services in young female breast cancer survivors. J Cancer Epidemiol 2012;2012:298745 [FREE Full text] [CrossRef] [Medline]
    89. Ware J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996 Mar;34(3):220-233. [Medline]
    90. Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Research in Psychology 2006 Jan;3(2):77-101. [CrossRef]
    91. Khoury MJ, Iademarco MF, Riley WT. Precision Public Health for the Era of Precision Medicine. Am J Prev Med 2016 Mar;50(3):398-401 [FREE Full text] [CrossRef] [Medline]
    92. Ademi Z, Watts GF, Pang J, Sijbrands EJG, van Bockxmeer FM, O'Leary P, et al. Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia. J Clin Lipidol 2014;8(4):390-400. [CrossRef] [Medline]
    93. Sie AS, Mensenkamp AR, Adang EMM, Ligtenberg MJL, Hoogerbrugge N. Fourfold increased detection of Lynch syndrome by raising age limit for tumour genetic testing from 50 to 70 years is cost-effective. Ann Oncol 2014 Oct;25(10):2001-2007. [CrossRef] [Medline]
    94. Snowsill T, Huxley N, Hoyle M, Jones-Hughes T, Coelho H, Cooper C, et al. A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome. Health Technol Assess 2014 Sep;18(58):1-406 [FREE Full text] [CrossRef] [Medline]
    95. Ned RM, Sijbrands EJG. Cascade Screening for Familial Hypercholesterolemia (FH). PLoS Curr 2011 May 23;3:RRN1238 [FREE Full text] [CrossRef] [Medline]
    96. Watts GF, Gidding S, Wierzbicki AS, Toth PP, Alonso R, Brown WV, International FH Foundation. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation: executive summary. J Atheroscler Thromb 2014;21(4):368-374. [Medline]
    97. Datta BN, McDowell IFW, Rees A. Integrating provision of specialist lipid services with cascade testing for familial hypercholesterolaemia. Curr Opin Lipidol 2010 Aug;21(4):366-371. [CrossRef] [Medline]
    98. Finnie R. Cascade screening for familial hypercholesterolaemia in Scotland. The British Journal of Diabetes & Vascular Disease 2010 Jun 21;10(3):123-125. [CrossRef]


    Abbreviations

    BRCA1: breast cancer 1
    BRCA2: breast cancer 2
    CTU: Clinical Trial Unit
    FH: familial hypercholesterolemia
    HBOC: hereditary breast/ovarian cancer syndrome
    HFTA: Federal Act on Human Genetic Testing
    LS: Lynch syndrome
    MMR: mismatch repair
    MSI-H: microsatellite instability


    Edited by G Eysenbach; submitted 02.06.17; peer-reviewed by E Sijbrands, P Schulz; comments to author 05.07.17; revised version received 15.07.17; accepted 15.07.17; published 20.09.17

    ©Maria C Katapodi, Valeria Viassolo, Maria Caiata-Zufferey, Christos Nikolaidis, Rosmarie Bührer-Landolt, Nicole Buerki, Rossella Graffeo, Henrik Csaba Horváth, Christian Kurzeder, Manuela Rabaglio, Michael Scharfe, Corinne Urech, Tobias E Erlanger, Nicole Probst-Hensch, Karl Heinimann, Viola Heinzelmann-Schwarz, Olivia Pagani, Pierre O. Chappuis. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 20.09.2017.

    This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on http://www.researchprotocols.org, as well as this copyright and license information must be included.